Dr Charles Shepherd ISLE OF MAN September 2015 ME/CFS: Research, Diagnosis and Management Bio Personal experience of PVFS++ following chickenpox + cerebellar encephalitic component PMH in hospital psychiatry Medical Adviser, ME Association MRC Expert Group on ME/CFS Research >> UK CMRC CMO Working Group DWP Fluctuating Conditions Group Disagreements, uncertainty, consensus… Background: WHO, DoH, DWP, NICE, MRC, Royal Colleges all accept this is a genuine and disabling illness BUT… 1 Nomenclature: ME, CFS, PVFS, SEID 2 Over 20 Clinical and Research definitions: Fukuda, Oxford, NICE, Canadian….. 3 Cause: Physical>>P+P> Psychological 4 Diagnosis: Often a long delay in making a diagnosis 5 Management: Rituximab >>> CBT and GET Result: ME/CFS rather like calling any form of arthritis a chronic joint pain syndrome and assuming they all have the same cause/disease pathway and management What is ME/CFS? Often fit young adults; children and adolescents as well Acute onset often following infection or immune system stressor - vaccination Muscle: exercise-induced fatigue and….. Post- exertional exacerbation of symptoms CNS: cognitive dysfunction: memory concentration info processing word finding Problems with balance, thermoregulation, alcohol intolerance ANS dysfunction: O intolerance, O hypotension and POTS; Ryynaud’s Immune system: sore throats and glands Pain in approx 75%: muscles, joints, neuropathic Non restorative sleep Epidemiology of ME/CFS Prevalence of 0.2 to 0.4% = ? 250,000 in UK, ?200 to 300 in IoM (pop 85,000) Commonest cause of long term sickness absence from school Adults onset: early 20s to mid 40s All social classes Strong female predominance Spectrum of severity: 25% severe at some stage >> severely neglected by the NHS Royal Free disease 1955 >> Lancet editorial: ME and Beard, BMJ 1970 >> mass hysteria Working in hospital medicine…………. Personal experience Extremely fit young adult Well motivated Infection ‘pre spots’ >> 48 hours >> exercise induced muscle fatigue, brain (balance/OI and cognitive++) and flu-like: not deconditioning Two years to get a diagnosis Well meaning but very bad management++ Work >> off sick >> work 1980s: ME >> CFS US and UK decision to rename and redefine ME as CFS >> Now over 20 diagnostic criteria for both clinical and research purposes UK: Oxford research (>> 2014 NIH report recommended removal), NICE clinical guideline (2007) US: 1994 Fukuda/CDC research Canadian, London (ME), International, IoM (2015)…… >> Messy compromise of ME/CFS: represents a very heterogenous group of clinical presentations and disease pathways IoM Report: February 2015 Lancet editorial: What’s in a name? (2015, v385, p663) Complex, serious multisystem DISEASE process Rename CFS and ME – systemic exertion intolerance syndrome (SEID) Mixed reaction from patient community New clinical definition >> 3 No longer a diagnosis of exclusion What causes ME/CFS: A three stage illness? Consensus: Predisposing factors Genetic predisposition increases susceptibility >> Consensus: Precipitating factors Viral infections++ other immune system stressors, including vaccinations – hepatitis B+ >> abnormal host response Gradual onset in up to 25% Debate: Perpetuating factors>> Evidence for cytokine mediated fatigue?? Viral infection >> low level immune system activation MRC at KCH: what happens to people with hepatitis C who are treated with interferon alpha and develop ME/CFS symptoms as a result? Hornig/Lipkin: Science Advances, 1 February 2015. Early cases (< 3 years) had a prominent activation in both proand anti-inflammatory cytokines (IL17a+). Correlation of cytokine alterations with illness duration suggesting immunopathology of ME/CFS is not static. Link to neuroinflammation through activated microglia? Is ME/CFS a Neuroimmune Disease?? >> Neuroendocrine dysfunction >> HPA downregulation and hypocortisolaemia Neurotransmitter dysfunction >> ?serotonin Autonomic NS dysfunction >> orthostatic intolerance and POTS/postural orthostatic tachycardia syndrome Low level neuroinflammation Neuroinflammation: Japanese group PET scans: neuroinflammation is higher in CFS/ME patients than in healthy people. Inflammation in cingulate cortex, hippocampus, amygdala, thalamus, midbrain, and pons elevated in a way that correlates with symptoms >> Impaired cognition>> amygdala Pain >> thalamic. Ref: Nakatomi et al. 2014, 55, 945 – 950. Journal of Nuclear Medicine, Ref: Nakatomi et al.JNM , 2014, 55, 945 - 950 Dorsal root ganglionitis Mitochondrial component to peripheral fatigue?? Prof Anne McArdle, University of Liverpool Arnold DL et al. Lancet, 1984, 1367 – 1369: Excessive intracellular acidosis of skeletal muscle on exercise in a patient with post viral fatigue syndrome (CS) Defect in energy producing component leads to fatigue…. But does the presence of dysfunctional mitochondria then activate a process that leads to chronic low grade inflammation? Research Initiatives…… MRC Expert Group on ME/CFS Research Identified research priorities including immune dysfunction and neuroinflammation >> 5 MRC funded studies costing £1.5m+ >>UK CFS/ME Research collaborative 2015 conference in Newcastle in October £££ Charity funding: ME biobank Diagnosis Consensus: Early and accurate diagnosis Timescale for diagnosis and management: First three months of post viral fatigue >> PVFS, which is often self resolving but can >> ME/CFS NICE and CMO WG: Working diagnosis of ME/CFS if symptoms persist beyond 3 to 4 months and no other explanation found. Don’t wait 6 months! Referral to hospital based services >> CMO report >>postcode lottery High rate of late diagnosis and misdiagnosis >>Newton et al, p23 MEA purple booklet Consensus: Routine investigations for TATT: NAD ESR + CRP/C reactive protein FBC +/- serum ferritin in adolescents Biochemistry: urea, electrolytes, calcium, creatinine, random blood sugar Liver function tests > ?PBC, ?hepatitis C ?NAFLD – raised transaminases, link to Gilbert’s syndrome Creatine kinase – ?hypothyroid myopathy Thyroid function tests and 9am cortisol Screen for coeliac disease - tissue transglutaminase antibody >> arthralgia, fatigue, IBS, mouth ulcers Urinalysis for protein, blood and glucose In some circumstances…. Pursue abnormal LFTSs: primary biliary cirrhosis (anti mitochondrial antibodies); Gilbert’s syndrome, NAFLD Raised calcium: ? sarcoidosis Joint pain+ Autoantibody screen for ? SLE (anti nuclear antibodies, anti DNA antibodies, complement) Infectious diseases: hep C (blood transfusion), Lyme; HIV, Q fever (contact with sheep), toxoplasmosis In some circumstances…. Dry eyes and dry mouth > ? Sjogren’s syndrome (Schirmer’s test for dry eyes) Low cortisol and suggestion of Addison’s (hypotension; low sodium; raised potassium) >> synacthen test Autonomic function tests >> tilt table test for POTS Muscle biopsy or MRS? Serum 25-hydroxyvitamin D (25-OHD) if at risk: restrictive diet; lack of sunlight; severe condition Debate: How should we manage ME/CFS patients Correct diagnosis > label > validation > uncertainties Specialist referral +/ 2007 NICE guideline on ME/CFS Activity management >> time and expertise Symptomatic relief Drugs aimed at underlying disease process Help with education, employment DWP benefits: ESA Information and support: MEA Management Report 2007 NICE Guideline Heavily criticised by patients for ‘one size fits all’ recommendations re CBT and GET Place on ‘static list’ in 2014 June 2014: Professor Mark Baker acknowledged that the guideline did need to be revised >> decision rests with NHS England NIH report 2015: ….behaviour therapy or graded exercise are not a primary treatment strategy and should only be used as a component of multimodal therapy Debate + Pacing vs GET Aim: balance rest with activity = Pacing Depends on Stage, Severity, Variability and symptoms such as autonomic and cognitive dysfunction Establish a comfortable baseline: physical and cognitive May involve increase/decrease in overall activity Gradual and flexible increases [Rest] >>> [Activity] >> [Rest] Accept progress may be slow and erratic Pacing vs GET – patient evidence GRADED EXERCISE THERAPY > More structured and progressive increase Clinical trial evidence +ve, including PACE trial MEA Management Report: N = 906 22% improved; 22% no change; 56% worse MEA: Abandon as a primary intervention PACING Clinical trial evidence –ve/not there Patient evidence +++ N = 2137: 72% improved; 24% no change; 4% worse Cognitive behaviour therapy Covers approaches based on abnormal illness beliefs/behaviours >> practical coping strategies RCT evidence: some +ve MEA Patient Evidence (N =998): 26% improved; 55% no benefit; 19% worse MEA Report: Help people who are having difficulty coping with ME/CFS and/or mental health problems Consensus: Drugs for symptomatic relief ANS dysfunction and POTS IBS symptomatology Nausea Pain Non restorative sleep NOT for fatigue, cognitive dysfunction Depression, Psychosocial distress…. ANS dysfunction Orthostatic intolerance very common POTS may occur: rise in pulse to over 120/min or 30 bpm on supine to standing Referral for tilt table testing? Self-help measures >> Increase hydration Salt where low blood pressure Drugs?? Midodrine?? IBS and nausea Very common overlap Exclude other explanations of fatigue + IBS:– coeliac; ovarian malignancy IBS-C; IBS-D and IBS mixed Drug approaches depending on type Dietary approaches FODMAP diet: Pain management Spectrum of severity Muscular, arthralgic and neuropathic OTC analgesics often of limited value Low dose sedating tricyclic >> ? liquid prep (25mg/5ml) Duloxetine/Cymbalta >> fibromyalgic component Anticonvulsants: Gabapentin and Pregabalin Opiates? Tramadol Non-drug options: acupuncture; TENS machine; relaxation Referral to pain clinic? Non restorative sleep Different types of sleep disturbance Sleep hygiene Short-acting hypnotics Low dose sedating tricyclic – eg amitriptyline 10mg to 30mg Melatonin?? MRC clinical trial of sodium oxybate Mental health problems Can co-exist Depression > psychological approaches first Drugs: commence with low dose and increase slowly Tricyclics – limited role due to sedation/side-effects SSRIs – with care as some very sensitive to low doses No evidence from RCTs that antidepressants are an effective form of treatment for ME/CFS Some problems with RCTs in relation to ME/CFS Not blinded Often rely of self-reported outcome measures Often fail to include objective outcome measures such as actographs, disability benefit and employment status Specialist centre treatment is not the same as what happens out in the real world Results do not match consistent patient evidence Can we treat underlying disease process? Not yet! Antiviral medication: valganciclovir? Immunotherapy: cytokine inhibition/Etanercept? Neuroendocrine: cortisone? thyroxine NO! Central fatigue: modafinil? Recent clinical trials: Ampligen – antiviral and immunomodulatory Rituximab >> Rituximab Rituximab Anti-CD20 antibody >> B cell depletion Used to treat lymphoma Significant response in 3 lymphoma cases with ME/CFS MOA? removal autoantibodies or reactivated infection Norwegian RCT 30 placebo/30 treated >> significant benefits Expensive Potential to cause serious++ side effects Norwegian phase 3 trial underway but not yet replicated Other key aspects of management DWP Benefits – ESA, PIP Education Employment and occupational health Key messages >>> Name that doctors and patients agree on Practical simple clinical definition (?IoM) Early and accurate diagnosis + proper investigation Pragmatic management guidance that is not based on the ‘one size fits all’ hypothesis NHS in patient and domiciliary services that cater for the severe end of the spectrum Research definition that recognises the heterogeneity of disease pathways involved and facilitates sub-grouping ME Association Literature pdf order form on the MEA website Online shop on the website ME Connect information and support: Tel: 0844 576 5326 Campaigning: benefits, services Political: APPG on ME Website: www.meassociation.org.uk and Facebook page